{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:52:04Z","timestamp":1780519924188,"version":"3.54.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Accurate genomic stratification is essential for guiding therapeutic decisions in myelofibrosis (MF), particularly regarding allogeneic stem cell transplant. Conventional chromosome banding analysis (CBA), however, has limited resolution and provides an informative karyotype in only about half of patients with MF. In a prospective series of 107 patients with primary or secondary MF, we compared optical genome mapping (OGM) plus targeted next-generation sequencing with CBA. OGM generated interpretable cytogenetic data for every sample, whereas CBA succeeded in fewer than half. In addition, OGM revealed structurally complex alterations and copy-neutral loss of heterozygosity that conventional methods missed. Integration of OGM results into contemporary prognostic models, including DIPSS-plus, GIPSS, and MIPSS70-plus version 2.0 (MIPSS70v2), refined risk allocation across the cohort. The greatest impact was observed for the transplant-oriented MIPSS70v2: the proportion of patients assigned to high-risk or very\u2013high-risk categories increased from 19% with CBA alone to 36% after incorporating OGM findings. Incorporation of OGM data enabled full risk stratification of all 57 individuals with nonevaluable CBA karyotypes; 16 were assigned directly to the high-risk or very high MIPSS70v2 risk categories, a reclassification with immediate implications for transplant referral and follow-up intensity. This study represents the largest prospective evaluation of OGM in MF, demonstrating that OGM overcomes the limitations of CBA, uncovers clinically relevant cryptic alterations, and refines prognostic stratification. These findings support integrating OGM with targeted sequencing as a step toward precision medicine in MF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017980","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:03:00Z","timestamp":1761674580000},"page":"379-391","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3362-0316","authenticated-orcid":false,"given":"\u00c1lvaro","family":"D\u00edaz-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-8803","authenticated-orcid":false,"given":"Elvira","family":"Mora","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"},{"name":"2Department of Hematology, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-1466","authenticated-orcid":false,"given":"Marta","family":"Garrote","sequence":"additional","affiliation":[{"name":"3Hematopathology Section, Pathology Department, Hospital Cl\u00ednic, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-5542","authenticated-orcid":false,"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Salido","sequence":"additional","affiliation":[{"name":"5Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain"},{"name":"6Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-2151","authenticated-orcid":false,"given":"Irene","family":"Pastor-Gal\u00e1n","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital Cl\u00ednico Universitario-Instituto de Investigaci\u00f3n Sanitaria Hospital Cl\u00ednico de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-2290","authenticated-orcid":false,"given":"Ruth","family":"Stuckey","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-3785","authenticated-orcid":false,"given":"Adela","family":"Cisneros","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Institut Catal\u00e0 d'Oncologia-Hospital Germans Trias i Pujol-Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4835-0381","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Domingo-Monfort","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hospital General de Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Uresandi-Iruin","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hospital Universitario Donostia, San Sebasti\u00e1n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagore","family":"Argoitia-Ituarte","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hospital Universitario Donostia, San Sebasti\u00e1n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Avetisyan","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-7914","authenticated-orcid":false,"given":"Cristian","family":"Garc\u00eda-Ruiz","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Torres-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Furi\u00f3","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"},{"name":"2Department of Hematology, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-7826","authenticated-orcid":false,"given":"Eduardo","family":"Arellano-Rodrigo","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hematological Malignancies Clinical Research Unit, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"V\u00e9lez","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0636-3358","authenticated-orcid":false,"given":"Eva","family":"Villam\u00f3n","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital Cl\u00ednico Universitario-Instituto de Investigaci\u00f3n Sanitaria Hospital Cl\u00ednico de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Segura-D\u00edaz","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital 12 de Octubre, Madrid, Spain"},{"name":"15Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-8145","authenticated-orcid":false,"given":"Blanca","family":"Espinet","sequence":"additional","affiliation":[{"name":"5Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain"},{"name":"6Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital Cl\u00ednico Universitario-Instituto de Investigaci\u00f3n Sanitaria Hospital Cl\u00ednico de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-403X","authenticated-orcid":false,"given":"Esperanza","family":"Such","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"},{"name":"2Department of Hematology, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"},{"name":"16Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"7","key":"2026012709565386800_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026012709565386800_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026012709565386800_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"16","key":"2026012709565386800_bib4","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026012709565386800_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2026012709565386800_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026012709565386800_bib7","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"2026012709565386800_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012709565386800_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026012709565386800_bib10","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2026012709565386800_bib11","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2026012709565386800_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-023-00869-9","article-title":"Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model","volume":"13","author":"Shide","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026012709565386800_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ajh.27226","article-title":"Comparative clinical and molecular landscape of primary and secondary myelofibrosis: superior performance of MIPSS70+ v2.0 over MYSEC-PM","volume":"99","author":"Guerra","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"2026012709565386800_bib14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","article-title":"European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms","volume":"33","author":"Rack","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"2026012709565386800_bib15","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/s41436-019-0545-7","article-title":"Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics (ACMG) and Cancer Genomics Consortium (CGC)","volume":"21","author":"Mikhail","year":"2019","journal-title":"Genet Med"},{"key":"2026012709565386800_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cancergen.2018.07.003","article-title":"Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: an evidence-based review of clinical utility from the Cancer Genomics Consortium (CGC) Working Group for myelodysplastic syndrome, myelodysplastic\/myeloproliferative and myeloproliferative neoplasms","volume":"228-229","author":"Kanagal-Shamanna","year":"2018","journal-title":"Cancer Genet"},{"issue":"15","key":"2026012709565386800_bib17","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026012709565386800_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ajh.27175","article-title":"A framework for the clinical implementation of optical genome mapping in hematologic malignancies","volume":"99","author":"Levy","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"2026012709565386800_bib19","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3390\/cancers15113039","article-title":"Cytogenetic assessment and risk stratification in myelofibrosis with optical genome mapping","volume":"15","author":"D\u00edaz-Gonz\u00e1lez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2026012709565386800_bib20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2026012709565386800_bib21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/gcc.22350","article-title":"Guidelines for genomic array analysis in acquired haematological neoplastic disorders","volume":"55","author":"Schoumans","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2026012709565386800_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"25","key":"2026012709565386800_bib23","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2016-02-696310","article-title":"Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency","volume":"127","author":"Theocharides","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026012709565386800_bib24","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.3324\/haematol.2018.202952","article-title":"Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease","volume":"104","author":"Stengel","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2026012709565386800_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3324\/haematol.2009.013623","article-title":"High-resolution single-nucleotide polymorphism array profiling in myeloproliferative neoplasms identifies novel genomic aberrations","volume":"95","author":"Stegelmann","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2026012709565386800_bib26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ajh.22166","article-title":"Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm","volume":"86","author":"Rumi","year":"2011","journal-title":"Am J Hematol"},{"issue":"21","key":"2026012709565386800_bib27","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2026012709565386800_bib28","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2026012709565386800_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"issue":"suppl 1","key":"2026012709565386800_bib30","first-page":"1","article-title":"ISCN 2024: an international system for human cytogenomic nomenclature (2024)","volume":"164","year":"2024","journal-title":"Cytogenet Genome Res"},{"issue":"4","key":"2026012709565386800_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.medcli.2019.11.007","article-title":"Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish registry of myelofibrosis","volume":"155","author":"Pastor-Gal\u00e1n","year":"2020","journal-title":"Med Clin (Barc) Engl Ed"},{"issue":"2","key":"2026012709565386800_bib32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/ijms21020654","article-title":"HMGA genes and proteins in development and evolution","volume":"21","author":"Vignali","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2026012709565386800_bib33","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","article-title":"3\u2032UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice","volume":"117","author":"Ikeda","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2026012709565386800_bib34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41375-024-02496-0","article-title":"HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis","volume":"39","author":"Handa","year":"2025","journal-title":"Leukemia"},{"issue":"15","key":"2026012709565386800_bib35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2017004457","article-title":"Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms","volume":"1","author":"Ueda","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2026012709565386800_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.08911.x","article-title":"TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele","volume":"156","author":"Bacher","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"2026012709565386800_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026012709565386800_bib38","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/leu.2009.82","article-title":"Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics","volume":"23","author":"Heinrichs","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2026012709565386800_bib39","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2007-05-092304","article-title":"Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS\/MPD, and MDS-derived AML","volume":"111","author":"Gondek","year":"2008","journal-title":"Blood"},{"issue":"31","key":"2026012709565386800_bib40","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1200\/JCO.2009.21.9840","article-title":"New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia","volume":"27","author":"Tiu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026012709565386800_bib41","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"2026012709565386800_bib42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/379\/2498046\/blooda_adv-2025-017980-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/379\/2498046\/blooda_adv-2025-017980-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:57:01Z","timestamp":1769525821000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/379\/547952\/Optical-genome-mapping-in-myelofibrosis-enhancing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017980","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,15]]}}}